Identification of a Biomarker Panel for Early Detection of Lung Cancer Patients-Reference-Cited by-同舟云学术

Identification of a Biomarker Panel for Early Detection of Lung Cancer Patients

Published:2019-08-13 Issue:9 Volume:18 Page:3369-3382
ISSN:1535-3893
Container-title:Journal of Proteome Research
language:en
Short-container-title:J. Proteome Res.

Author:

Geary Bethany¹²^ORCID,Walker Michael J.²,Snow Joseph T.²³,Lee David C. H.¹,Pernemalm Maria⁴,Maleki-Dizaji Saeedeh²,Azadbakht Narges²,Apostolidou Sophia⁵,Barnes Julie⁶,Krysiak Piotr⁷,Shah Rajesh⁷,Booton Richard⁸,Dive Caroline⁹¹⁰,Crosbie Philip A.¹⁵⁸,Whetton Anthony D.¹³¹⁰

Affiliation:

1. Stoller Biomarker Discovery Centre, Institute of Cancer Sciences, Faculty of Medical and Human Sciences, University of Manchester, Manchester M13 9PL, United Kingdom

2. Stem Cell and Leukaemia Proteomics Laboratory, Institute of Cancer Sciences, Faculty of Medical and Human Sciences, University of Manchester, Manchester M13 9PL, United Kingdom

3. Department of Earth Sciences, University of Oxford, Oxford OX1 2JD, United Kingdom

4. Science for Life Laboratory, Department of Oncology and Pathology, Karolinska Institutet, 171 77 Solna, Sweden

5. Gynaecological Cancer Research Centre, Department of Women’s Cancer, Institute for Women’s Health, University College London, London WC1E 6BT, United Kingdom

6. Abcodia, Cambourne, Cambridge CB23 6EB, United Kingdom

7. Department of Thoracic Surgery, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester M23 9LT, United Kingdom

8. North West Lung Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester M23 9LT, United Kingdom

9. Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester M13 9PL, United Kingdom

10. Cancer Research UK Lung Cancer Centre of Excellence, Manchester M13 9PL, United Kingdom

Funder

Medical Research Council

Department of Health

National Institute for Health Research

Roy Castle Lung Cancer Foundation

Cancer Research UK

Eve Appeal

North West Lung Centre

Publisher

American Chemical Society (ACS)

Subject

General Chemistry,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jproteome.9b00287

Reference45 articles.

1. National Cancer Intelligence Network. Stage Breakdown by CCG 2014; http://www.ncin.org.uk/publications/survival_by_stage (accessed Dec 7, 2018).

2. ISDN Scotland. Detect Cancer Early Staging Data; http://www.isdscotland.org/Health-Topics/Cancer/Detect-Cancer-Early/ (accessed Dec 13, 2018).

3. Northern Ireland Cancer Registry. Incidence by stage 2010–2014; http://www.qub.ac.uk/research-centres/nicr/CancerInformation/official-statistics/ (accessed Dec 13, 2018).

4. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening

5. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of a proteomic signature coupled with the kidney failure risk equation in predicting end stage kidney disease in a chronic kidney disease cohort;Clinical Proteomics;2024-05-18

2. Proteomics: Unraveling the Cross Talk Between Innate Immunity and Disease Pathophysiology, Diagnostics, and Treatment Options;Advances in Experimental Medicine and Biology;2024

3. Proteomic analysis identifies subgroups of patients with active systemic lupus erythematosus;Clinical Proteomics;2023-07-29

4. Proteomic signature associated with chronic kidney disease (CKD) progression identified by data-independent acquisition mass spectrometry;Clinical Proteomics;2023-04-20

5. A Novel Blood Proteomic Signature for Prostate Cancer;Cancers;2023-02-07